Empagliflozin After Heart Attack Shows Modest Value at High Price in German Model
A German health insurance model projects that early empagliflozin after heart attack yields modest quality-adjusted survival gains at an incremental ...
A German health insurance model projects that early empagliflozin after heart attack yields modest quality-adjusted survival gains at an incremental ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.